At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 72 enrolled
Drug / intervention
MB-6 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase II Trial of MB-6 Plus FOLFOX4 for Metastatic Colorectal Cancer
In Brief
A Phase 2 clinical trial evaluating MB-6 and Placebo for Colorectal Cancer. Completed, enrolled 72 participants across 1 site.
Detailed Summary
This is a randomized, double-blind, parallel group, placebo-controlled study evaluate the preliminary efficacy and safety of MB-6 (320 mg/capsule, 6 capsules tid) versus placebo in addition to standard chemotherapy in the treatment of patients with metastatic colorectal cancer.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsColorectal Cancer
CountriesTaiwan
Collaborators--
Timeline
Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
Enrollment StartOct 2009
First PostedJan 2010
Primary CompletionApr 2011
Study CompletionDec 2011
TodayJul 2026
First PostedJan 13, 2010
Enrollment StartOct 1, 2009
Primary CompletionApr 1, 2011
Study CompletionDec 1, 2011
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 16.5 years ago
Interventions
MB-6drug
6# TID with meal
Placebodrug
6# TID with meal